Home > Journals > Minerva Cardioangiologica > Past Issues > Articles online first > Minerva Cardioangiologica 2018 Feb 01

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,695


eTOC

 

Minerva Cardioangiologica 2018 Feb 01

DOI: 10.23736/S0026-4725.18.04619-4

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Parenteral antithrombotic therapy during primary percutaneous coronary intervention

Federico FORTUNI 1, 2 , Marco FERLINI 2, Sergio LEONARDI 2

1 Università degli Studi di Pavia, Pavia, Italy; 2 Fondazione IRCCS Policlinico San Matteo, Pavia, Italy


PDF  


Acute myocardial infarction (AMI) is a major cause of morbidity, mortality and disability worldwide. ST-segment elevation myocardial infarction (STEMI) accounts for 25-40% of AMI presentations. Arterial thrombosis due to atherosclerotic plaque rupture with formation of an occlusive thrombus, is the main cause of STEMI . Platelets and coagulation factors are the two principal elements involved in this process. The main goal of STEMI treatment is the early reperfusion. Prompt primary percutaneous coronary intervention (pPCI) together with an appropriate antithrombotic therapy are the treatment of choice in this setting. In this chapter, we provide an overview of currently available parenteral antithrombotic therapies used in patients with STEMI undergoing pPCI.


KEY WORDS: Parenteral Antithrombotic therapy during pPCI - STEMI - Pharmacological management of STEMI

top of page

Publication History

Article first published online: February 01, 2018
Manuscript accepted: January 29, 2018
Manuscript received: January 18, 2018

Cite this article as

Fortuni F, Ferlini M, Leonardi S. Parenteral antithrombotic therapy during primary percutaneous coronary intervention. Minerva Cardioangiol 2018 Feb 01. DOI: 10.23736/S0026-4725.18.04619-4

Corresponding author e-mail

fortuni@alice.it